Asclepius Life Sciences Fund, L.P. is uniquely positioned to participate in the rapidly evolving life sciences landscape.

Our nationally recognized, veteran team has extensive operational expertise in life sciences and investment expertise in maximizing long-term risk-adjusted returns.  Our team’s strategic and operational experience covers most therapeutic classes of life sciences including strategic planning, corporate development, operations management, product development, clinical and regulatory, product marketing and sales management.  Management is aligned with shareholder interests in creating fundamental value via ownership and performance-based compensation.

Michael J. Levas

Co-Founder, Senior Managing Principal & Chief Investment Officer

Michael J. Levas is the Co-Founder, Senior Managing Principal & Chief Investment Officer of Asclepius Life Sciences Fund, L.P. and Co-Founder & Chief Investment Officer of Asclepius Ventures, L.P.

Mr. Levas manages investments in multi-asset classes in public and private companies within a construct to de-risk investments.  In the public markets, Asclepius utilizes scientific, financial and technical analysis to manage specific opportunities by identifying and capitalizing on catalyst-driven events.  In the private markets, Asclepius de-risks investments by establishing deep insights on the drug development and approval process in the highest growth areas of Life Sciences including Rare Diseases, Immuno-Oncology, Inflammatory Diseases, Specialty Pharma and Medical Devices.

Mr. Levas has been in the investment management business for over thirty years and is the Founder, former Senior Managing Principal & Chief Investment Officer at the Olympian Group of Investment Management Companies. Previously, he was a VP and Portfolio Manager in the Private Client Group at Lehman Brothers Inc. Prior to that, he was a VP with SG Cowen, UBS PaineWebber, and Bear Stearns where he managed both institutional and retail portfolios. Mr. Levas is the former founder and managing principal of Olympian Securities LLC, & is former licensed Series 24 general securities principal, Series 7 general securities representative, and a current Series 65, investment adviser representative with Olympian Investment Management LLC. Mr. Levas is also the former founder and principal of Olympian Futures LLC, a former (NFA) registered I.B., and a former licensed Series 3 associated person.

Mr. Levas currently holds the Chartered Portfolio Manager (CPM) designation from the American Academy of Financial Management. Mr. Levas completed investment management studies at Harvard Business School, and Global Investment Risk Management at The University of Oxford Said Business School. Additionally, Mr. Levas completed the Hedge Fund Programme at The London Business School. He is a current member of the CFA Institute, Securities Traders Association of NY, and formerly served on the 2008/2009 board of directors of The Hedge Fund Association and was a Federal registered lobbyist for the H.F.A.

Mr. Levas is a frequent conference speaker and commentator on the financial markets & asset management industry. He has been featured throughout the U.S., Canada, Latin America, Europe, Asia and in numerous publications, and media outlets including BusinessWeek, Dow Jones Newswires, Smart Money, Hedge Fund Manager Week, Absolute Return, Canadian Hedge Watch, Euromoney, Economic Times, International Securities Finance, Buy-Side Technology, Securities Industry News, Alternative Investment Review, Advanced Trading, Markets Media Magazine, The Trade News, TradeTech, Waters, Reuters, Bloomberg, CCTV Intl. & National Public Radio.

His specialties include:  momentum trading, actively managed portfolios, multi asset & macro trading, FX trading, listed option trading, call & put writing, and spreads. In addition, Mr. Levas has extensive executive and senior level operational experience in various aspects of founding and managing asset management firms, broker-dealers & hedge funds.

To read Mr. Levas’s full bio on LinkedIn, please click here.

Steve Glover

Co-Founder & Managing Principal

Steve Glover is the Co-Founder and Managing Principal for Asclepius Life Sciences Fund, L.P.

He has extensive experience and success in biopharmaceutical company turnarounds and growing top line revenues, with a focus on business strategy.  His experience spans Fortune 100, start up and entrepreneurial environments. He has extensive success in turnarounds and growing the top line, with a focus on business strategy, corporate development, product development, commercialization and business optimization. His transaction experience covers over 25 transactions totaling over $10 billion. His strategic and operational experience, which covers most therapeutic classes of biopharmaceuticals, includes strategic planning, corporate development, operations management, product development, clinical and regulatory, product marketing and sales management.

Currently Mr. Glover is Co-founder, President and CEO of Variant Pharmaceuticals. Variant is an emerging specialty pharmaceutical company leveraging advanced proprietary technologies to develop two best-in-class drug therapies for patients with rare diseases or other conditions with limited or sub-optimal treatment options. Before founding Variant, Mr. Glover was Co-founder and Chief Business Officer of Coherus BioSciences. Coherus BioSciences is a late-stage biologics platform-company focused on delivering high-quality biosimilar therapeutics. Coherus (CHRS) became a publicly traded company in November of 2014.

Prior to co-founding Coherus, he was the President of Insmed Therapeutic Proteins as well as EVP and Chief Business Officer of Insmed Incorporated. At Insmed, Mr. Glover was responsible for the creation of the biosimilar business unit and the divestiture of the business to Merck. As EVP and Chief Business Officer he led Insmed’s strategic review process which resulted in the merger of Insmed and Transave. Prior to Insmed, Mr. Glover held the position of Senior Vice President and General Manager at Andrx Laboratories and Andrx Therapeutics, both divisions of Andrx Corporation. He earlier held multiple executive roles in sales, marketing and operational roles at Roche Laboratories, Amgen Inc. and IMS Health. Currently Mr. Glover serves on the Board of Directors of Variant Pharmaceuticals, Two-B Pharma and InflamaCore. Additionally Mr. Glover serves as an Executive in Residence at the University of Miami U Innovation Life Sciences Office. Mr. Glover received his B.S. in Marketing from Illinois State University in 1982.

Dr. Steven Gerst

Co-Founder & Principal

Dr. Steven Gerst is the Co-Founder and Principal of Asclepius Life Sciences Fund L.P.  Dr. Gerst holds Series 7  and Series 65 Securities Licenses.  He focuses on biopharma and medical technology.

Dr. Gerst is a graduate of the Columbia University College of Physicians and Surgeons (M.D.) and is an Aresty Scholar of the Wharton School of Business at the University of Pennsylvania.  He is a graduate of Columbia College (B.A.), Columbia School of Public Health – Health Administration (M.P.H.) and the Goizuetta School of Business at Emory University (M.B.A.).  Dr. Gerst is Board Certified in Medical Management and is Diplomat in the American College of Healthcare Executives.

Dr. Gerst holds certificates of completion in additional course work from Harvard Business School, Harvard Law School, Harvard School of Public Health and the Wharton School of Business at the University of Pennsylvania.  He is on the Faculty at the University of Miami School of Health Sciences and Nursing (on-line program) and at the Miller School of Medicine working for the Vice Provost in the Office of the Chief Innovation Officer as an “Entrepreneur– in-Residence.”

Dr. Gerst is formerly Senior Consultant and Regional Medical Director for what is now PricewaterhouseCoopers, LLP. He was President of Columbia/HCA’s PPO division nationally under Florida’s current Governor, Rick Scott, and Vice President of the corporation (NYSE:HCA). Prior to that, he was Assistant Vice President of Crawford & Company (Atlanta; NYSE:CRDA and CRDB) the world’s largest independent claims management company, with more than 700 offices in 70 countries. At Crawford & Company, he built the first nationwide PPO for AIG, Boeing and other Crawford clients with 1,200 hospitals and 120,000 physicians.

He began his career with what is now Premier, Inc. (NASDAQ: PINC) serving 3,750 member and owner hospitals where he built HMOs, PPOs and ran the Utilization Management consulting division. Premier is the nation’s largest Health Care Group Purchasing Organization. He is also Dean Emeritus of the Masters of Science Program in Applied Health Informatics at Bryan University (Los Angeles, Sacramento, Toronto and Phoenix) where he serves on the Board of Advisors and has taught on the faculty (http://bryanuniversity.edu/advisory-board-members/?). He is heavily involved in the medical device industry, remote patient monitoring and telemedicine and is currently working on projects with Intel, AT&T, Citrix, Cognizant, ADT, Qualcomm, Epic and Cerner developing connected health platforms for large integrated delivery systems and IPA groups.

Norman “Nick” Carey


Norman “Nick” Carey is a Trader with Asclepius Life Sciences Fund, L.P.

Mr. Carey has been in the investment management business for over 25 years. He is currently the senior managing principal at Watch Hill Investments, Boston, Massachusetts where he has successfully managed and traded over $220 million dollars of securities for a private fund since 1996. Mr. Carey also was formerly associated with Bear Stearns, Donaldson, Lufkin & Jenrette and Prudential Securities in their Boston offices from 1992 through 1996.

Mr. Carey is a graduate of Boston College with a Bachelor of Arts degree in English. In addition to Mr. Levas, Mr. Carey will be overseeing the daily trading of the Asclepius Life Sciences Fund and will act in the capacity of Assistant Head Trader.


| Accredited Investors

The information contained in this web site has been prepared solely for accredited investors. It is for informational purposes and is not an offer to sell or purchase or a solicitation of an offer to sell or purchase any interests or shares in any of the funds managed by Asclepius Investment Strategies, LLC Such offers are made only by way of a private offering memorandum delivered to qualified investors.

| Contact

641 Lexington Avenue, Suite 1337
New York, NY 10022
Phone: (212) 634-6440
Fax: (212) 634-6480